Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01712984 |
Recruitment Status :
Completed
First Posted : October 24, 2012
Results First Posted : February 10, 2014
Last Update Posted : May 7, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The aim of the study is to demonstrate safety and immunogenicity of the quadrivalent influenza intradermal (QIV-ID) vaccine compared to the trivalent influenza vaccine (TIV) containing the B strain from the primary (Yamagata) lineage (TIV-ID1) and the trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage (TIV-ID2) vaccines in producing protection against four strains of influenza virus.
Primary Objective:
- To demonstrate that QIV-ID induces an immune response (as assessed by hemagglutination inhibition (HAI) geometric mean titers (GMTs) and seroconversion rates) that is non-inferior to responses induced by TIV-ID1 and TIV-ID2 for the 4 virus strains at 28 days post-vaccination.
Secondary Objectives:
- To demonstrate that each B strain in QIV-ID induces an immune response (as assessed by HAI GMTs and seroconversion rates) that is superior to the response induced by the TIV-ID that does not contain the corresponding B strain.
- To describe the rate of post-vaccination seroprotection induced by QIV-ID and TIV-ID.
- To describe post-vaccination immunogenicity stratified by age (18-49 years and 50-64 years), race, ethnicity, gender, previous vaccination status, and baseline seropositivity status.
- To describe the safety profile for subjects who receive QIV-ID and TIV-ID.
Observational Objectives:
- To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 2 or Grade 3 solicited systemic reactions combined
- To demonstrate non-inferiority of QIV-ID compared to TIV-ID in terms of all Grade 3 solicited injection site reactions combined.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Influenza | Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 3360 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 Through 64 Years |
Study Start Date : | October 2012 |
Actual Primary Completion Date : | June 2013 |
Actual Study Completion Date : | October 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: QIV ID Vaccine Group
Participants will receive the intradermal quadrivalent influenza vaccine
|
Biological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation
0.1mL, Intradermal
Other Name: QIV ID |
Active Comparator: TIV ID1 Vaccine Group
Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage
|
Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal
0.1mL, Intradermal
Other Name: Fluzone® Intradermal |
Active Comparator: TIV ID2 Group
Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage
|
Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
0.1mL, Intradermal
Other Name: Fluzone® Intradermal |
- Geometric Mean Titers Against the Influenza Virus Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route [ Time Frame: Day 28 post-vaccination ]Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay.
- Number of Participants With Seroconversion to Influenza Virus Vaccine Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route [ Time Frame: Day 28 post-vaccination ]Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay. Seroconversion was defined as titer< 10 (1/dil) on Day 0 and post injection titer ≥ 40 (1/dil) on Day 28, or titer ≥10 (1/dil) on Day 0 and a ≥4 fold increase in titer (1/dil) on Day 28).
- Geometric Mean Titers Against the Influenza Virus Antigens Before and Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route [ Time Frame: Day 0 (pre-vaccination) and Day 28 post-vaccination ]Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay.
- Number of Participants With Seroprotection Against Influenza Vaccine Antigens Before (Baseline) and Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route [ Time Frame: Day 0 (pre-vaccination) and Day 28 post-vaccination ]Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay. Seroprotection was defined as titer ≥ 40 [1/dil] at baseline and 28 days after vaccination.
- Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route [ Time Frame: Day 0 up to Day 7 post-vaccination ]Solicited injection site: Pain, Erythema, Swelling, Induration, Ecchymosis, and Pruritus; Solicited systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering. Grade 3 injection site: Pain and Pruritus Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis >100 mm. Grade 3 systemic reactions: Fever ≥39˚C; Headache, Malaise, Myalgia, and Shivering Significant preventing daily activity.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 64 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged 18 through 64 years on the day of inclusion
- Informed consent form (ICF) has been signed and dated
- Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria:
- Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)
- Participation at the time of trial enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following trial vaccination
- Vaccination against influenza in the past 6 months
- Receipt of immune globulins, blood or blood-derived products in the past 3 months
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
- History of thrombocytopenia
- Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion
- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- Current alcohol abuse or drug addiction
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- Identified as an Investigator or employee of the Investigator or trial center with direct involvement in the proposed trial, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed trial
- Personal or family history of Guillain-Barré Syndrome
- Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy, and subjects who have a history of neoplastic disease and who have been disease free for ≥ 5 years.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01712984
United States, Alabama | |
Hoover, Alabama, United States, 35216 | |
Huntsville, Alabama, United States, 35802 | |
United States, Arizona | |
Chandler, Arizona, United States, 85224 | |
Mesa, Arizona, United States, 85213 | |
Phoenix, Arizona, United States, 85020 | |
Tucson, Arizona, United States, 85704 | |
United States, California | |
Chula Vista, California, United States, 91911 | |
Sacramento, California, United States, 95816 | |
San Diego, California, United States, 92103 | |
United States, Connecticut | |
Milford, Connecticut, United States, 06460 | |
United States, Florida | |
Coral Gables, Florida, United States, 33134 | |
Melbourne, Florida, United States, 32935 | |
Pinellas Park, Florida, United States, 33781 | |
South Miami, Florida, United States, 33143 | |
United States, Idaho | |
Boise, Idaho, United States, 83642 | |
United States, Iowa | |
Iowa City, Iowa, United States, 52242 | |
United States, Kansas | |
Overland Park, Kansas, United States, 66212 | |
Wichita, Kansas, United States, 67207 | |
United States, Missouri | |
Kansas City, Missouri, United States, 64114 | |
Springfield, Missouri, United States, 65802 | |
St. Louis, Missouri, United States, 63104 | |
United States, Nebraska | |
Omaha, Nebraska, United States, 68134 | |
United States, New York | |
Binghamton, New York, United States, 13901 | |
Rochester, New York, United States, 14609 | |
Rochester, New York, United States, 14621 | |
United States, Pennsylvania | |
Allentown, Pennsylvania, United States, 18102 | |
Bensalem, Pennsylvania, United States, 19020 | |
United States, Rhode Island | |
Warwick, Rhode Island, United States, 02886 | |
United States, South Carolina | |
Mt. Pleasant, South Carolina, United States, 29464 | |
United States, South Dakota | |
Dakota Dunes, South Dakota, United States, 57049 | |
United States, Texas | |
Austin, Texas, United States, 78745 | |
Fort Worth, Texas, United States, 76107 | |
Fort Worth, Texas, United States, 76135 | |
San Angelo, Texas, United States, 76904 | |
United States, Utah | |
Salt Lake City, Utah, United States, 84109 | |
Salt Lake City, Utah, United States, 84121 | |
West Jordan, Utah, United States, 84088 | |
United States, Wisconsin | |
Marshfield, Wisconsin, United States, 54449 |
Study Director: | Medical Director | Sanofi Pasteur Inc. |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Sanofi Pasteur, a Sanofi Company |
ClinicalTrials.gov Identifier: | NCT01712984 |
Other Study ID Numbers: |
QID01 U1111-1124-8066 ( Other Identifier: WHO ) |
First Posted: | October 24, 2012 Key Record Dates |
Results First Posted: | February 10, 2014 |
Last Update Posted: | May 7, 2015 |
Last Verified: | April 2015 |
Influenza Fluzone® Intradermal vaccine Influenza Virus Vaccine USP Quadrivalent Influenza Virus Vaccine USP Trivalent Types A and B |
Influenza, Human Respiratory Tract Infections Infections Orthomyxoviridae Infections RNA Virus Infections Virus Diseases Respiratory Tract Diseases Fluconazole Vaccines Immunologic Factors Physiological Effects of Drugs |
Antifungal Agents Anti-Infective Agents 14-alpha Demethylase Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Steroid Synthesis Inhibitors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C19 Inhibitors |